If You Invested in Insight Molecular Diagnostics Inc. (IMDX)

Insight Molecular Diagnostics Inc. (Nasdaq: IMDX), also known as iMDx, is a precision diagnostics technology company in the healthcare sector focused on diagnostics and research. The company’s stated mission is to democratize access to novel molecular diagnostic testing in order to improve patient outcomes, with an initial strategic focus on transplant rejection testing.

According to company disclosures, iMDx utilizes a proprietary approach to quantify donor-derived cell-free DNA (dd-cfDNA), an established molecular biomarker of transplanted organ rejection. dd-cfDNA has been highlighted in multiple scientific publications and position papers referenced by the company as a promising marker for monitoring organ health and transplant rejection risk. iMDx reports that its scientists in Germany and the United States have contributed over many years to the scientific work that helped establish dd-cfDNA as a trusted biomarker of transplant rejection.

Insight Molecular Diagnostics is headquartered in Nashville, Tennessee, having moved its headquarters from Irvine, California. The company’s common stock trades on the Nasdaq Capital Market under the symbol IMDX, following a name and ticker transition from Oncocyte Corp. (OCX). The company describes itself as a pioneering precision diagnostics technology business within the broader diagnostics and research industry.

Transplant-focused molecular diagnostics

iMDx’s flagship transplant testing technology is commercialized under the GraftAssure brand. This technology quantifies dd-cfDNA and is designed to support kidney transplant management, including surveillance for rejection and monitoring of treatment response. The company states that it is pursuing a kitted assay strategy intended to enable decentralized or in-house testing at transplant centers, in contrast to centralized lab-only models that have historically been common in transplant diagnostics.

The GraftAssure family of assays, as described in company news releases, currently includes:

• GraftAssureCore – A laboratory-developed test (LDT) performed at iMDx’s CLIA-certified laboratory in Nashville. The company reports that this test is reimbursed by the Centers for Medicare & Medicaid Services (CMS) for certain transplant rejection surveillance indications. iMDx has indicated that its previously marketed VitaGraft Kidney LDT has been rebranded under the GraftAssureCore name.
• GraftAssureIQ – A research-use-only (RUO) test kit intended and labeled for non-clinical applications. Company communications describe GraftAssureIQ as enabling in-house dd-cfDNA testing in transplant research settings and supporting scientific studies at transplant centers and research hospitals.
• GraftAssureDx – An in vitro diagnostic (IVD) test kit in development for use in clinical decision-making. iMDx has stated that GraftAssureDx is being prepared for regulatory submissions, including a planned de novo submission to the U.S. Food and Drug Administration (FDA) for marketing authorization as a regulated medical device.

Across multiple shareholder letters and press releases, iMDx emphasizes that all three GraftAssure offerings are based on the same underlying dd-cfDNA technology, which uses a digital PCR-based approach. The company highlights potential clinical applications such as early detection of kidney transplant rejection, longitudinal surveillance, and monitoring of therapeutic response in complex clinical scenarios.

Clinical and scientific positioning

Insight Molecular Diagnostics frequently references peer-reviewed research and collaborative studies involving its dd-cfDNA assay. Company communications describe data in areas such as:

• Head-to-head performance of the GraftAssure assay compared with other transplant rejection testing approaches.
• Use of dd-cfDNA to detect kidney transplant rejection earlier than certain standard protocols.
• Case-based evidence in which GraftAssure monitoring supported clinical decision-making, including a published case of a kidney transplant patient with post-transplant lymphoproliferative disorder treated with CD19 CAR-T therapy, where dd-cfDNA monitoring helped confirm the absence of rejection.

iMDx also discusses the development of a combined dd-cfDNA score that incorporates both absolute and relative measures of donor-derived cell-free DNA. The company indicates that this combined score is intended to improve the positive predictive value of rejection testing and reduce unnecessary biopsies. In addition, iMDx refers to a testing frequency concept sometimes described as the “Berlin protocol” for certain high-risk transplant patients, which the company plans to evaluate further through registry data.

Registry programs and clinical engagement

To support broader clinical adoption and evidence generation, Insight Molecular Diagnostics has announced a multi-center registry program centered on its kidney transplant rejection assay. The company states that it aims to enroll thousands of patients across numerous transplant centers over several years, generating a large volume of real-world dd-cfDNA data. This registry is intended to:

• Evaluate the clinical utility of the combined dd-cfDNA score.
• Assess accelerated monitoring protocols for high-risk patients.
• Provide hospital-based real-world evidence that can inform clinical practice and payer discussions.

iMDx reports active engagement with transplant centers in the United States and internationally, including clinical trial sites and research partners using GraftAssureIQ. Company updates describe participation in major transplant and immunogenetics conferences, where iMDx and collaborators present data on dd-cfDNA testing, in-house assay implementation, and potential workflow advantages for transplant centers.

Regulatory and reimbursement context

In its public communications, Insight Molecular Diagnostics highlights several regulatory and reimbursement milestones related to its transplant testing platform. These include:

• Coverage decisions from CMS for its LDT-based dd-cfDNA assay for kidney transplant rejection surveillance, including certain high-risk patient populations.
• Ongoing work toward FDA marketing authorization for the GraftAssureDx IVD kit, including clinical trials, reproducibility studies, software validation, and quality management system development.
• Preparations for regulatory submissions in other regions, such as European regulatory pathways, supported by audits under ISO 13485 medical device standards.

According to company statements, these regulatory and reimbursement efforts are intended to support a business model in which transplant centers can either send samples to iMDx’s central CLIA lab (via GraftAssureCore) or, following regulatory clearance, run kitted assays in-house (via GraftAssureDx), with research partners using GraftAssureIQ in non-clinical studies.

Corporate background

Insight Molecular Diagnostics Inc. is incorporated in California and files periodic and current reports with the U.S. Securities and Exchange Commission (SEC). The company’s SEC filings and press releases note that it was formerly known as Oncocyte Corp. (OCX) before adopting the Insight Molecular Diagnostics name and IMDX ticker symbol. The company positions itself within the healthcare diagnostics and research industry, with a precision diagnostics focus and a transplant-centered initial market.

Through its public communications, iMDx consistently describes its overarching goal as improving access to molecular diagnostic testing for transplant patients and their care teams, with dd-cfDNA-based assays as its primary technology platform.